Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 2.12
TROV's Cash to Debt is ranked higher than
61% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. TROV: 2.12 )
TROV' s 10-Year Cash to Debt Range
Min: 2.12   Max: No Debt
Current: 2.12

Equity to Asset 0.38
TROV's Equity to Asset is ranked higher than
58% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. TROV: 0.38 )
TROV' s 10-Year Equity to Asset Range
Min: -4.07   Max: 0.75
Current: 0.38

-4.07
0.75
F-Score: 1
Z-Score: 0.24
M-Score: -5.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -4904.43
TROV's Operating margin (%) is ranked higher than
53% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. TROV: -4904.43 )
TROV' s 10-Year Operating margin (%) Range
Min: -4127.8   Max: -1077.56
Current: -4904.43

-4127.8
-1077.56
Net-margin (%) -3937.64
TROV's Net-margin (%) is ranked higher than
54% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. TROV: -3937.64 )
TROV' s 10-Year Net-margin (%) Range
Min: -4560.23   Max: -867.83
Current: -3937.64

-4560.23
-867.83
ROE (%) -59.97
TROV's ROE (%) is ranked higher than
65% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. TROV: -59.97 )
TROV' s 10-Year ROE (%) Range
Min: -104.7   Max: -104.7
Current: -59.97

ROA (%) -35.64
TROV's ROA (%) is ranked higher than
70% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. TROV: -35.64 )
TROV' s 10-Year ROA (%) Range
Min: -288.72   Max: -60.85
Current: -35.64

-288.72
-60.85
ROC (Joel Greenblatt) (%) -1657.65
TROV's ROC (Joel Greenblatt) (%) is ranked higher than
65% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. TROV: -1657.65 )
TROV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -25886.96   Max: -2125.45
Current: -1657.65

-25886.96
-2125.45
» TROV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with TROV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.30
TROV's P/B is ranked higher than
68% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. TROV: 9.30 )
TROV' s 10-Year P/B Range
Min: 3.26   Max: 69.3
Current: 9.3

3.26
69.3
P/S 430.90
TROV's P/S is ranked higher than
66% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. TROV: 430.90 )
TROV' s 10-Year P/S Range
Min: 80   Max: 674
Current: 430.9

80
674
EV-to-EBIT -8.99
TROV's EV-to-EBIT is ranked higher than
72% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TROV: -8.99 )
TROV' s 10-Year EV-to-EBIT Range
Min: -27.2   Max: -3
Current: -8.99

-27.2
-3
Current Ratio 10.11
TROV's Current Ratio is ranked higher than
87% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. TROV: 10.11 )
TROV' s 10-Year Current Ratio Range
Min: 0.46   Max: 20.57
Current: 10.11

0.46
20.57
Quick Ratio 10.11
TROV's Quick Ratio is ranked higher than
88% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. TROV: 10.11 )
TROV' s 10-Year Quick Ratio Range
Min: 0.46   Max: 20.57
Current: 10.11

0.46
20.57
Days Sales Outstanding 83.51
TROV's Days Sales Outstanding is ranked higher than
78% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. TROV: 83.51 )
TROV' s 10-Year Days Sales Outstanding Range
Min: 102.91   Max: 140.06
Current: 83.51

102.91
140.06

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.04
TROV's Price/Net Cash is ranked higher than
84% of the 1357 Companies
in the Global Biotechnology industry.

( Industry Median: 56.66 vs. TROV: 11.04 )
TROV' s 10-Year Price/Net Cash Range
Min: 4.17   Max: 208.67
Current: 11.04

4.17
208.67
Price/Net Current Asset Value 10.66
TROV's Price/Net Current Asset Value is ranked higher than
83% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 36.79 vs. TROV: 10.66 )
TROV' s 10-Year Price/Net Current Asset Value Range
Min: 4.07   Max: 156.5
Current: 10.66

4.07
156.5
Price/Tangible Book 9.68
TROV's Price/Tangible Book is ranked higher than
74% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. TROV: 9.68 )
TROV' s 10-Year Price/Tangible Book Range
Min: 3.8   Max: 62.6
Current: 9.68

3.8
62.6
Price/Median PS Value 1.81
TROV's Price/Median PS Value is ranked higher than
78% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. TROV: 1.81 )
TROV' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 1.66
Current: 1.81

0.32
1.66
Earnings Yield (Greenblatt) -11.50
TROV's Earnings Yield (Greenblatt) is ranked higher than
61% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. TROV: -11.50 )
TROV' s 10-Year Earnings Yield (Greenblatt) Range
Min: -18.1   Max: 0
Current: -11.5

-18.1
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:XE7A.Germany,
TrovaGene, Inc., was incorporated in the State of Delaware on April 26, 2002 as Used Kar Parts, Inc. On July 2, 2004, the Company acquired Xenomics, a California corporation, which was developing and commercializing TrDNA technology. As part of the acquisition, its corporate name was changed to Xenomics, Inc. (Xenomics) The Company re-domesticated its state of incorporation from Florida to Delaware and its name was changed to Trovagene, Inc. It is a development stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. Its novel tests predominantly use transrenal DNA, or Tr-DNA, and transrenal RNA, or Tr-RNA. The Company is leveraging its proprietary urine-based molecular diagnostic technology for the detection of cell-free DNA and RNA originating from diseased cell death that can be isolated from urine and detected to improve disease management. These genetic materials are also collectively referred to as cell-free nucleic acids, which result when cells in the body die and release their DNA or RNA into the bloodstream. Its fundamental urine-based molecular diagnostic platform is protected by a strong intellectual property portfolio. The Company's developed significant intellectual property around cell-free nucleic acids in urine, the extraction of cell-free nucleic acids from urine, as well as novel assay designs, particularly its proprietary non-naturally occurring primers. As of February 28, 2014, our property portfolio consists of over 130 issued patents and over 47 pending patent applications. The Company faces direct competition in the area of transrenal cell-free DNA or RNA detection and analysis is precluded by our growing patent estate. Its competitors include medical diagnostic companies, most of which have financial, technical, and marketing resources significantly greater than our resources.
» More Articles for TROV

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
TrovaGene Inc (TROV) Sees Bridger Management Buy More Shares; Other Stocks Roberto Mignone Loves Mar 03 2015
Trovagene Schedules Release of Fourth Quarter and Year End 2014 Financial Results and Investor... Feb 26 2015
Trovagene Schedules Release of Fourth Quarter and Year End 2014 Financial Results and Investor... Feb 26 2015
TROVAGENE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 11 2015
Trovagene, Inc. Announces Closing of Public Offering of Common Stock Feb 11 2015
Trovagene, Inc. Announces Closing of Public Offering of Common Stock Feb 11 2015
Trovagene, Inc. to Present at Leerink Global Healthcare Conference Feb 10 2015
TROVAGENE, INC. Files SEC form 8-K, Other Events Feb 09 2015
Clinical Results Demonstrate High Sensitivity of Trovagene's Urine-Based HPV Assay for the Detection... Feb 09 2015
TROVAGENE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Feb 06 2015
TrovaGene Falls Sharply; Prices Offering Below Expectations Feb 06 2015
Trovagene, Inc. Announces Pricing of Public Offering of Common Stock Feb 06 2015
TROVAGENE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 05 2015
Trovagene, Inc. Announces Public Offering of Common Stock Feb 05 2015
TrovaGene Partners with Leading Cancer Research Institutes - Analyst Blog Jan 26 2015
TROVAGENE, INC. Files SEC form 8-K, Other Events Jan 26 2015
Trovagene's Chief Scientific Officer to Present Precision Cancer Monitoring (SM) Platform Overview... Jan 26 2015
TROVAGENE, INC. Files SEC form 8-K, Other Events Jan 21 2015
Trovagene Expands Collaboration with Genomac to Demonstrate Clinical Utility in Lung and Colorectal... Jan 21 2015
TROVAGENE, INC. Files SEC form 8-K, Other Events Jan 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK